Melanoma Clinical Trial
— REGESMOHSOfficial title:
Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs]
Verified date | May 2020 |
Source | Fundación Academia Española de Dermatología |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs
surgery, and patient, tumor and technique factors related to adverse events and tumor
recurrence.
REGESMOHS is a prospective cohort, including all patients considered for Mohs surgery in
participating centers. All consecutive patients are included. The only exclusion criteria are
being under 18-years-old or legally incompetent. Pre-planned follow-up is as required by
common clinical practice, but at least once a year for the study period.
Status | Completed |
Enrollment | 6000 |
Est. completion date | February 29, 2020 |
Est. primary completion date | February 29, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All consecutive patients considered for Mohs surgery Exclusion Criteria: - Under 18 years-old - Legally incompetent |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario de Cruces | Barakaldo | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Quirón Teknon | Barcelona | |
Spain | Hospital Santa Creu i Sant Pau | Barcelona | |
Spain | Complejo Hospitalario Universitario de Guadalajara | Guadalajara | |
Spain | Complejo Asistencial Universitario de León | León | |
Spain | Clínica Quirón | Madrid | |
Spain | Hospital de la Princesa | Madrid | |
Spain | Hospital Gregorio Marañon | Madrid | |
Spain | Hospital La Zarzuela | Madrid | |
Spain | Hospital Universitario Fundación de Alcorcón | Madrid | |
Spain | Clínica Universitaria de Navarra | Pamplona | |
Spain | Complexo Hospitalario Universitario de Santiago | Santiago de Compostela | |
Spain | Hospital Manises | Valencia | |
Spain | Instituto Valenciano de Oncología | Valencia |
Lead Sponsor | Collaborator |
---|---|
Fundación Academia Española de Dermatología | Roche Pharma AG |
Spain,
Alonso-Alonso T, Redondo-Bellon P, Sanmartín-Jiménez O, de Eusebio-Murillo E, García-Doval I, Rodríguez-Prieto MÁ. Census of Centers That Perform Mohs' Micrographic Surgery in Spain and Description of Their Activity: A Feasibility Study for the Mohs' Micrographic Surgery Registry of the Foundation of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2015 Nov;106(9):764-6. doi: 10.1016/j.ad.2015.02.014. Epub 2015 Jun 23. English, Spanish. — View Citation
Camarero-Mulas C, Delgado Jiménez Y, Sanmartín-Jiménez O, Garcés JR, Rodríguez-Prieto MA, Alonso-Alonso T, Miñano Medrano R, López-Estebaranz JL, de Eusebio Murillo E, Redondo P, Ciudad-Blanco C, Toll-Abelló A, Artola Igarza JL, Allende Markixana I, Suarez Fernández R, Alfaro Rubio A, Alonso Pacheco ML, Vázquez-Veiga H, de la Cueva Dobao P, Ruiz-Salas V, Vilarrasa Rull E, Barchino L, Morales-Gordillo V, Ocerin-Guerra I, Navarro Tejedor R, Hueso L, Mayor Arenal M, Seoane-Pose MJ, Cano-Martinez N, Garcia-Doval I, Descalzo MA; REGESMOHS (Registro Español de Cirugía de Mohs). Mohs micrographic surgery in the elderly: comparison of tumours, surgery and first-year follow-up in patients younger and older than 80 years old in REGESMOHS. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):108-112. doi: 10.1111/jdv.14586. Epub 2017 Oct 5. — View Citation
de Eusebio Murillo E, Martín Fuentes A, Ruiz-Salas V, Garcés JR, Miñano Medrano R, López-Estebaranz JL, Alonso-Alonso T, Rodríguez-Prieto MÁ, Delgado Jiménez Y, Morales V, Redondo Bellón P, Manubens-Mercadé E, Sanmartín-Jiménez O, Guillén Barona C, Cabeza R, Cano N, Toll-Abelló A, Navarro Tejedor R, Artola Igarza JL, Allende Markixana I, Alfaro Rubio A, Ciudad Blanco C, Vázquez-Veiga H, Barchino Ortiz L, Descalzo MA, García-Doval I. Characterization of Surgical Procedures in the Spanish Mohs Surgery Registry (REGESMOHS) for 2013-2015. Actas Dermosifiliogr. 2017 Nov;108(9):836-843. doi: 10.1016/j.ad.2017.04.018. Epub 2017 Aug 9. English, Spanish. — View Citation
Delgado Jiménez Y, Camarero-Mulas C, Sanmartín-Jiménez O, Garcés JR, Rodríguez-Prieto MÃ, Alonso-Alonso T, Miñano Medrano R, López-Estebaranz JL, de Eusebio Murillo E, Redondo P, Ciudad-Blanco C, Toll A, Artola Igarza JL, Allende Markixana I, Suarez Fernández R, Alfaro Rubio A, Alonso Pacheco ML, Vázquez-Veiga H, de la Cueva Dobao P, Ruiz-Salas V, Vilarrasa E, Barchino L, Morales-Gordillo V, Ocerin-Guerra I, Navarro Tejedor R, Hueso L, Mayor Arenal M, Seoane-Pose MJ, Cano-Martinez N, Garcia-Doval I, Descalzo MA; REGESMOHS. Differences of Mohs micrographic surgery in basal cell carcinoma versus squamous cell carcinoma. Int J Dermatol. 2018 Nov;57(11):1375-1381. doi: 10.1111/ijd.14223. Epub 2018 Sep 23. — View Citation
Ruiz-Salas V, Garcés JR, Alonso-Alonso T, Rodríguez-Prieto MA, Toll-Abelló A, Eusebio Murillo E, Miñano R, López-Estebaranz JL, Sanmartín-Jiménez O, Guillén Barona C, Allende Markixana I, Alfaro Rubio A, Delgado Jiménez Y, Navarro R, Barchino Ortiz L, Lázaro Ochaita P, Vilarasa E, Ciudad Blanco C, Vázquez-Veiga H, Artola Igarza JL, Alonso ML, García-Doval I, Descalzo MA, Redondo Bellón P. Description of patients excluded for Mohs surgery after pre-surgical evaluation: data from the Regesmohs Spanish registry. Actas Dermosifiliogr. 2018 May;109(4):346-350. doi: 10.1016/j.ad.2017.11.008. Epub 2018 Jan 17. English, Spanish. — View Citation
Ruiz-Salas V, Garcés JR, Miñano Medrano R, Alonso-Alonso T, Rodríguez-Prieto MÁ, López-Estebaranz JL, Sanmartín-Jiménez O, Guillén Barona C, Delgado Jiménez Y, Toll-Abelló A, Vargas Diez E, Ciudad Blanco C, Alfaro Rubio A, Allende Markixana I, de Eusebio Murillo E, Manubens-Mercadé E, Vázquez-Veiga H, Barchino Ortiz L, García-Doval I, Redondo Bellón P. Description of Patients Undergoing Mohs Surgery in Spain: Initial Report on Data From the Spanish Registry of Mohs Surgery (REGESMOHS). Actas Dermosifiliogr. 2015 Sep;106(7):562-8. doi: 10.1016/j.ad.2015.04.002. Epub 2015 May 28. English, Spanish. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor recurrence | 6 years | ||
Secondary | Short term outcomes | Bleeding, infection, abnormal scar, necrosis | 1 month | |
Secondary | Use of resources | Need for admission, type of anesthesia, number of surgical steps, participating doctors,time in surgery room. | During surgery | |
Secondary | Impairments of body function and structure | presence of: abnormal scar, ectropion, nostril alteration, oral sphincter incompetence,other | 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|